AcelRx is focused on maintaining commercial sales performance of DSUVIA, plans to focus DSUVIA commercialization efforts on select markets and certain potential national accounts, DSUVIA partnering discussions with potential commercial entities, the potential European launch of DZUVEO by Aguettant, plans to pursue a potential Emergency Use Authorization for Niyad and establish a supply chain to support such efforts, plans to reduce cash burn and potentially reduce operating costs, plans to potentially file NDAs for developmental pre-filled syringe products and the timing of such filings, expected effect and scope of cost savings arising from restructuring efforts, and potential near-term value-creating catalysts arising under the development pipeline.